ASX listed companies show their financial standing in their recently published half-yearly reports.
Of the cannabis-only companies, most are showing revenue – however the majority is from overseas sales.
Elixinol Global (AXS: EXL) is the clear leader, showing sales revenue of $36.3 million. However Elixinol Global includes subsidiaries Hemp Foods Australia, Elixinol USA, and more.
MGC Pharma (AXS: MXC) comes in second with $882,136 in sales revenue, mainly from their European operations.
Athea Group (AXS: AGH) backs up their statements about patient acquisition, showing on-shore revenue generation of $174,000.
The table below outlines the 11 ASX listed companies focussed solely on cannabis.
| Company | Market Cap | Cannabis Revenue | Other Revenue | Expenses | Profit/Loss |
| Elixinol | $438,420,000 | $36,299,000 | $326,000 | $42,390,000 | -$5,765,000 |
| Cann Group | $259,850,000 | $2,550 | $985,616 | $5,128,323 | -$4,140,157 |
| AusCann | $125,180,000 | $0 | $466,305 | $4,904,677 | -$4,438,372 |
| Botanix | $95,190,000 | $0 |
$450,725 |
$3,640,974 |
-$3,190,249 |
| Althea | $81,320,000 | $174,000 | $8,000 | $2,548,000 | -$2,366,000 |
| THC Global | $65,550,000 | $815 | $2,715,991 | $8,566,911 | -$5,850,920 |
| Creso | $51,490,000 | $570,904 | $112,806 | $8,794,499 | -$8,110,789 |
| MGC Pharma | $47,300,000 | $882,136 | $226,528 | $3,793,229 | -$2,684,565 |
| Zelda | $43,810,000 | $0 | $59,527 | $1,334,852 | -$1,275,325 |
| BOD Australia | $31,570,000 | $699,769* | $485,655 | $3,739,691 | -$2,554,267 |
| CannPal | $10,710,000 | $0 | $349,679 | $1,057,007 | -$707,328 |
* BOD Australia does not differentiate between its cannabis revenue and revenue generated from other goods.
‘Other Revenue’ is generated from interest on cash reserves, non-cannabis related revenue, and R&D tax credits.
Expenses between these companies also varies significantly. The majority of expenses come from operational costs – employee benefits, legal fee’s, marketing, cost of goods, admin fees, office fees, etc.
Creso (ASX: CPH), however, paid almost $1.5m in ‘consultancy and facilitation fees’, and over $6m in ‘share based payment expenses’, while Botanix Pharma (ASX: BOT) spent around $7.5m in research and development.
AusCann (ASX: AC8), one of the leading companies in terms of valuation ($125.18m) made no revenue, invested no money in research and development, and seems to have little in terms of assets other than $41.7m in cash.
Beyond these companies, there are an additional 17 ASX listed companies not solely involved in cannabis.
2 Comments
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
[…] a look into their financial report for the second half of 2018 seems to display a different. The company generated no sales revenue, […]
[…] 6-12 months, to where it now sits at $0.34 ($41m market cap). However, they generated one of the highest revenues for ASX cannabis specific companies, and have a clear strategy for growth, commercialisation, and eventual product registration both in […]